论文部分内容阅读
现今临床上用于治疗白细胞减少症的药物很多,有的虽有一定的疗效,但停药后白细胞又很快下降,其疗效均不甚满意,因此寻找疗效更好的升白药物,是临床实际的需要。1973年,北京制药工业研究所研制成升白新。学名为地菲林葡萄糖甙,是从小蘖科植物山荷叶中提取地菲林作甙元,其9位羟基上再接上葡萄糖制得。经我们实验室对小鼠、大鼠、狗、猴等动物作毒理实验表明,升白新对大鼠慢性苯中毒及小鼠急性苯中毒引起的白细胞减少症有较明显的升白细胞作用,并具有毒性较低,治疗指数大和合成线路较易等优点。自1977年起,该药已在北京、上海、武汉、苏州等城市五个医院内,对各
There are many drugs used for the treatment of leukopenia in clinical practice. Although some drugs have a certain effect, the white blood cells drop rapidly after drug withdrawal. The efficacy of these drugs is not satisfactory. Therefore, it is clinically important to find better drugs for improving leukopenia. The actual needs. In 1973, the Beijing Institute of Pharmaceutical Industry developed into new white. The scientific name is feilin glucoside, which is extracted from the lotus leaves of the plant Asteraceae and used as the aglycon. The 9-position hydroxyl is connected with glucose. The toxicological experiments conducted by our laboratory on mice, rats, dogs, monkeys and other animals have shown that Shengbaixin has obvious leucocyte-promoting effects on rat chronic benzene poisoning and leukopenia caused by acute benzene poisoning in mice. It has the advantages of low toxicity, large therapeutic index, and easy synthesis route. Since 1977, the drug has been in five hospitals in cities including Beijing, Shanghai, Wuhan and Suzhou.